Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

BACKGROUND: This phase 1b study evaluated an enteric-coated tablet (ECT) formulation of the investigational Aurora A kinase inhibitor, alisertib (MLN8237). METHODS: Patients with advanced, non-hematologic malignancies received oral alisertib ECT for 7 days BID followed by 14 days treatment-free (21-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Falchook, Gerald, Kurzrock, Razelle, Gouw, Launce, Hong, David, McGregor, Kimberly A., Zhou, Xiaofei, Shi, Hongliang, Fingert, Howard, Sharma, Sunil
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4229392/
https://ncbi.nlm.nih.gov/pubmed/24879333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0121-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados